Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$2.98 -2.9%	$3.95	$2.76 ▼ $6.98	$167.96M	1.21	178,783 shs	132,720 shs
CCCC C4 Therapeutics	$2.35 +0.9%	$1.91	$1.09 ▼ $7.22	$165.83M	2.97	1.71 million shs	998,197 shs
CRBU Caribou Biosciences	$2.00 +2.6%	$1.65	$0.66 ▼ $3.00	$181.59M	2.55	1.73 million shs	1.28 million shs
RENB Renovaro	$0.24 -1.4%	$0.30	$0.22 ▼ $2.10	$41.57M	0.54	1.27 million shs	476,121 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	-2.93%	+2.05%	-24.37%	-27.32%	-49.41%
CCCC C4 Therapeutics	+0.86%	-8.91%	+11.37%	+70.29%	-58.55%
CRBU Caribou Biosciences	+2.56%	+10.50%	+24.22%	+113.13%	+5.26%
RENB Renovaro	-1.45%	+5.78%	-15.00%	-26.09%	-65.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	2.3497 of 5 stars	3.3	2.0	1.5	1.7	1.3
CCCC C4 Therapeutics	2.1428 of 5 stars	3.2	2.0	2.3	1.7	0.6
CRBU Caribou Biosciences	2.8333 of 5 stars	3.5	5.0	2.0	1.7	0.0
RENB Renovaro	1.8964 of 5 stars	0.0	5.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	2.50	Moderate Buy	$6.00	101.34% Upside
CCCC C4 Therapeutics	2.33	Hold	$8.00	240.43% Upside
CRBU Caribou Biosciences	3.00	Buy	$6.67	233.33% Upside
RENB Renovaro	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RENB, CCCC, CRBU, and BTMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	0.83	$0.74 per share	4.01	($1.44) per share	-2.07
CCCC C4 Therapeutics	$35.58M	4.70	N/A	N/A	$2.45 per share	0.96
CRBU Caribou Biosciences	$9.99M	18.64	N/A	N/A	$1.78 per share	1.12
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.90	3.31	5.52	N/A	15.73%	-21.00%	18.26%	N/A
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	N/A
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	9/29/2025 (Estimated)

Latest RENB, CCCC, CRBU, and BTMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	0.98	1.14
CCCC C4 Therapeutics	N/A	5.06	5.06
CRBU Caribou Biosciences	N/A	6.66	7.63
RENB Renovaro	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
CCCC C4 Therapeutics	78.81%
CRBU Caribou Biosciences	77.51%
RENB Renovaro	71.41%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
CCCC C4 Therapeutics	8.73%
CRBU Caribou Biosciences	8.28%
RENB Renovaro	0.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	54.71 million	41.58 million	Not Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.30 million	Optionable
RENB Renovaro	20	172.12 million	171.26 million	Optionable

RENB, CCCC, CRBU, and BTMD Headlines

Recent News About These Companies

Renovaro (NASDAQ:RENB) Stock Price Up 1.8% - What's Next?

August 14 at 3:27 AM | americanbankingnews.com

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

August 8, 2025 | accessnewswire.comA

Renovaro Biosciences Granted Nasdaq Compliance Extension

August 6, 2025 | tipranks.com

AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks

July 30, 2025 | tmcnet.com

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

July 28, 2025 | accessnewswire.comA

Renovaro (NASDAQ:RENB) Trading 0.1% Higher - Time to Buy?

July 23, 2025 | marketbeat.com

Renovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

July 17, 2025 | finanznachrichten.de

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

July 17, 2025 | accessnewswire.comA

Renovaro Biosciences Receives Nasdaq Compliance Notice

July 14, 2025 | tipranks.com

Renovaro Strengthens Balance Sheet Through Debt ... - Morningstar

July 11, 2025 | morningstar.comM

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

July 9, 2025 | accessnewswire.comA

Renovaro Biosciences Restructures Debt with Exchange Agreement

July 9, 2025 | tipranks.com

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - Nasdaq

July 2, 2025 | nasdaq.com

Renovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30, 2025 | accessnewswire.comA

Renovaro subsidiary secures patent for drug discovery AI

June 5, 2025 | uk.investing.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingen

June 5, 2025 | nl.investing.com

RENB stock touches 52-week low at $0.27 amid market challenges

June 5, 2025 | investing.com

Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics

June 5, 2025 | msn.com

Renovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkeling

June 3, 2025 | nl.investing.com

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, CCCC, CRBU, and BTMD Company Descriptions

biote NASDAQ:BTMD

$2.98 -0.09 (-2.93%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.96 -0.02 (-0.67%)

As of 08/14/2025 07:46 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

C4 Therapeutics NASDAQ:CCCC

$2.35 +0.02 (+0.86%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.35 0.00 (-0.21%)

As of 08/14/2025 07:59 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Caribou Biosciences NASDAQ:CRBU

$2.00 +0.05 (+2.56%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08/14/2025 07:29 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Renovaro NASDAQ:RENB

$0.24 0.00 (-1.45%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.24 +0.01 (+2.94%)

As of 08/14/2025 07:40 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time